Therapeutics was Cellectis’s largest revenue line in fiscal 2018, bringing in $21.02M of $21.43M (98%).
| Products and services [axis] | FY 2014 | FY 2016 | FY 2017 | FY 2018 |
|---|---|---|---|---|
| Therapeutics | $44.41M | $24.68M | $21.02M | |
| Plants | $585.00K | $508.00K | $414.00K | |
| Total | $44.99M | $25.19M | $21.43M |
Cellectis brought in $21.43M from its two revenue lines in fiscal 2018, the year ended December 31, 2018. That was down 14.9% from $25.19M in fiscal 2017. Therapeutics was the largest at $21.02M (98.1%), ahead of Plants at $414.00K (1.9%).
From fiscal 2016 to 2018, combined revenue from these revenue lines fell from $44.99M to $21.43M, a compound annual decline of 31.0%. Therapeutics' share of the total fell from 98.7% to 98.1%.
Cellectis (CLLS) reports its revenue by products and services [axis]. In fiscal 2018, Therapeutics was its largest revenue line, bringing in $21.02M (98.1% of the total), followed by Plants at $414.00K (1.9%).
Therapeutics was Cellectis' largest revenue line in fiscal 2018, bringing in $21.02M, or 98.1% of the $21.43M total across its two revenue lines.
Every figure comes from Cellectis' annual financial filings, as reported. Each line keeps the name Cellectis gives it, and years follow its fiscal calendar.
Cellectis' revenue by products and services [axis] goes back to fiscal 2014, with figures through fiscal 2018. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.